[1] |
SUN Qiyue, ZHAO Ronghua, BAO Lei, GUO Shanshan, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing.
Safe doses of Lingyang Ganmao oral liquid for children based on the multi-animal model
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 121-126.
|
[2] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[3] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[4] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
[5] |
TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing.
Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
|
[6] |
HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong.
Automatic monitoring and assessment of antibiotics-related thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
|
[7] |
LIU Yuanxi, GU Donglin, WANG Qi, YAO Lingwen, WANG Ying, JIN Hongyu, MA Shuangcheng.
Determination of 87 types of pesticide residues in Polygoni Multiflori Radix by LC-MS/MS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 601-608.
|
[8] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[9] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[10] |
ZHANG Zhiqi, GUO Mingxing, XU Ye, ZHANG Jian, LIN Jun, CUI Xiangli.
One case of tacrolimus-caused reversible posterior leukoencephalopathy syndrome after renal transplantation in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 465-468.
|
[11] |
WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili.
Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
|
[12] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[13] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[14] |
JIA Zhaoguang, XU Wenshuai, JI Li’na, WANG Linlin, ZHAO Li’na, ZHAO Jingquan, MU Xiangdong.
Diagnosis and treatment of mycoplasma pneumoniae pneumonia in children and rational administration of related drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1391-1395.
|
[15] |
PENG Jing, TUO Yali, LI Qiaoling, ZHOU Rong, LI Xinlin, PENG Hui.
Data analysis of adverse events of clobazam among children based on foreign pharmacovigilance safety spontaneous reporting system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1264-1268.
|